VRAX

SEC filing VRAX Reports 88% Specificity, 92% PPV for ViraxImmune™ in Long COVID Trial, Targets $1.4B+ US Testing Market

7d ago

Scanner Large up move: 53.1% (3.0x normal daily movement)

14d ago

SEC filing VRAX Announces $6.4M Cash Position, $25B PAIS Market, ViraxImmune™ LDT Pathway, ISO 13485 Certified, Debt-Free, $2.6M Valuation Gap

49d ago

SEC filing VRAX Reports No Revenue, $0 Net Income, Files 6-K for April 2026

52d ago

News Apollo Seeks to Reassure Clients About Executives’ Epstein Ties

103d ago

News Cisco CEO Robbins Outlines AI Platform Strategy Across Networking and Security

104d ago

News Apollo Global Management CFO Sees Higher Rates Ahead as Origination Hits $300B, FRE Jumps 23%

104d ago

News Apollo Global Management Touts $40T Private Credit Opportunity, AI Financing and Fund XI at BofA Conference

106d ago

Scanner Unusual volume (2.2x average)

117d ago